Skip to main content
2023 Guide to Patient Support Services

Servier

2023 PSS Guide

ServierONE Patient Support Services

800-813-5905

The ServierONE patient support program provides patients with financial assistance and one-on-one support when prescribed a Servier oncology product (Table).

ServierONE Patient Support Services

This program offers several patient support services to help patients throughout their treatment journey, including a Free Product Program, Financial Assistance Program, and the ONE for ALL Program for Asparlas and Oncaspar, as well as the Tibsovo Copay Program, the Tibsovo Patient Assistance Program, the Tibsovo Quick-Start Program, and the ONE for CCA Program.

Free Product Program/Financial Assistance Program

Servier offers financial support for patients taking Asparlas and Oncaspar who meet eligibility requirements. To learn more, contact a Servier Case Manager at 800-813-5905 or e-mail This email address is being protected from spambots. You need JavaScript enabled to view it..

ONE for ALL

This site was designed for patients and their families and provides helpful resources and tools for navigating treatment care, costs, and education throughout their journey. Encourage the families of your patients with acute lymphoblastic leukemia (ALL) to visit www.ServierOneforAll.com/s/.

Tibsovo Copay Program

This program lowers costs for eligible patients to no more than $25 per prescription if their copay exceeds that amount, with a maximum benefit of $25,000 per calendar year. There are no income restrictions. Patients may be eligible if they:

  • Have commercial insurance
  • Are NOT participating in government healthcare programs.

To register, visit ServierOne-copay.com.

Tibsovo Patient Assistance Program

The Patient Assistance Program offers free prescriptions to eligible uninsured or underinsured patients and may apply to patients with commercial or state/government insurance. Patients may be eligible if they fit these criteria:

  • Are uninsured or underinsured
  • Some commercial and government insured (Medicare D)
  • Reside in the United States or Puerto Rico
  • Household annual income does not exceed 600% of US federal poverty level
  • Financial hardship: family income is less than $175,000 annually; greater than or equal to 5% ratio of out-of-pocket expenses.

To apply on behalf of patients, visit www.servierone.com/s/hcp/tibsovo.

Tibsovo QuickStart Program

The QuickStart Program provides a free 30-day prescription (allowing for 1 refill, for a total of 60 days) to eligible new patients experiencing coverage delays of 5 or more days after submission of a completed prior authorization.

To apply on behalf of patients, visit www.servierone.com/s/hcp/tibsovo.

ONE for CCA

This site was designed for patients and provides helpful resources and tools for navigating treatment care, costs, and education throughout their journey. Encourage your patients with cholangiocarcinoma (CCA) to visit www.OneforCCA.com/s/.

TABLE Servier Oncology Drugs

Drugs
Indications
Patient support programs

Drug
Asparlas (calaspargase pegol-mknl)
Indications
As a component of a multiagent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 month to 21 years
Patient support programs

Drug
Oncaspar (pegaspargas)
Indications
As a component of a multiagent chemotherapeutic regimen for the treatment of pediatric and adult patients with ALL and hypersensitivity to native forms of L-asparaginase
Patient support programs

Drug
Tibsovo (ivosidenib tablets)
Indications
Patient support programs

Tibsovo (ivosidenib tablets) Indications

In combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy; treatment of adult patients with relapsed or refractory AML with a susceptible IDH1 mutation as detected by an FDA-approved test; treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation as detected by an FDA-approved test

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"
Comments
(Optional)